A US-based cardiology podcast created in 2019 by Dr Amit Goyal and Dr Daniel Ambinder. It provides in-depth discussions of clinical cardiology topics, current guidelines, and expert interviews to enhance cardiology education and patient care.
High-risk pulmonary embolism can cause right ventricular failure before hypotension develops. Surgical decisions depend on clot chronicity and accessibility, while VA-ECMO may provide circulatory support. Sedation or intubation can remove compensatory mechanisms and precipitate collapse.
The MINT trial did not demonstrate a statistically significant primary-outcome benefit from liberal transfusion in myocardial infarction with anaemia, despite favourable mortality signals. A Class IIb recommendation supports individualised decisions based on ongoing ischaemia, revascularisation and clinical stability.
Deciding on an implantable cardioverter defibrillator after myocardial infarction requires time for ventricular recovery and reassessment after revascularisation. Early trials reduced arrhythmic deaths without overall survival benefit, and selected exceptions need a specific documented rationale.
Ventricular septal rupture after myocardial infarction can deteriorate despite initial haemodynamic stability; early involvement of a cardiac surgical centre and temporary support may help. Apparent benefits of delayed repair are vulnerable to selection and survivor bias.
Microaxial flow pumps may benefit selected patients with ST-elevation myocardial infarction complicated by severe or refractory cardiogenic shock. Device-related complications, physiological limitations and trial uncertainty explain why the recommendation remains conditional rather than universal.
Acute pulmonary embolism management uses clinical risk and cardiopulmonary deterioration to guide anticoagulation and escalation. Trials of invasive treatments require careful interpretation, while persistent symptoms after the acute event warrant follow-up for chronic thromboembolic disease.
Anticoagulation during PCI for non-ST-elevation acute coronary syndrome requires balancing ischaemia and bleeding, with unfractionated heparin the class 1 option discussed, fondaparinux unsuitable alone during PCI, and historical bivalirudin comparisons complicated by unequal IIb/IIIa inhibitor use.
Cangrelor provides rapid intravenous P2Y12 inhibition during percutaneous coronary intervention when oral treatment is unreliable, with a minimum two-hour infusion, drug-specific transition to oral agents and selective rather than routine glycoprotein IIb/IIIa inhibitor use.
Fibrinolysis for ST-elevation myocardial infarction requires clopidogrel plus parenteral anticoagulation, with important dosing changes from age 75; continued anticoagulation during transfer helps reduce recurrent ischaemic events while renal function and bleeding risk shape drug choice.
After out-of-hospital cardiac arrest, stable patients without STEMI or other high-risk features can follow delayed or selective angiography, while serial ECGs, lateral or posterior views, arrest characteristics and prognosis help identify those who still warrant earlier invasive assessment.
.svg)